Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
editorial
. 1991 Jun;63(6):837–840. doi: 10.1038/bjc.1991.186

Prognostic factors in the non-Hodgkin's lymphomas--a time for consensus?

J A Child
PMCID: PMC1972544  PMID: 2069841

Full text

PDF
837

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aisenberg A. C., Wilkes B. M., Jacobson J. O. The bcl-2 gene is rearranged in many diffuse B-cell lymphomas. Blood. 1988 Apr;71(4):969–972. [PubMed] [Google Scholar]
  2. Akerman M., Brandt L., Johnson A., Olsson H. Mitotic activity in non-Hodgkin's lymphoma. Relation to the Kiel classification and to prognosis. Br J Cancer. 1987 Feb;55(2):219–223. doi: 10.1038/bjc.1987.41. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Anderson H., Scarffe J. H., Swindell R., Crowther D. Serum beta 2-microglobulin in patients with non-Hodgkin's lymphoma. Eur J Cancer Clin Oncol. 1983 Mar;19(3):327–331. doi: 10.1016/0277-5379(83)90129-3. [DOI] [PubMed] [Google Scholar]
  4. Armitage J. O., Weisenburger D. D., Hutchins M., Moravec D. F., Dowling M., Sorensen S., Mailliard J., Okerbloom J., Johnson P. S., Howe D. Chemotherapy for diffuse large-cell lymphoma--rapidly responding patients have more durable remissions. J Clin Oncol. 1986 Feb;4(2):160–164. doi: 10.1200/JCO.1986.4.2.160. [DOI] [PubMed] [Google Scholar]
  5. BIERMAN H. R., HILL B. R., REINHARDT L., EMORY E. Correlation of serum lactic dehydrogenase activity with the clinical status of patients with cancer, lymphomas, and the leukemias. Cancer Res. 1957 Aug;17(7):660–667. [PubMed] [Google Scholar]
  6. Brittinger G., Bartels H., Common H., Dühmke E., Fülle H. H., Gunzer U., Gyenes T., Heinz R., König E., Meusers P. Clinical and prognostic relevance of the Kiel classification of non-Hodgkin lymphomas results of a prospective multicenter study by the Kiel Lymphoma Study Group. Hematol Oncol. 1984 Jul-Sep;2(3):269–306. doi: 10.1002/hon.2900020306. [DOI] [PubMed] [Google Scholar]
  7. Cabanillas F., Burke J. S., Smith T. L., Moon T. E., Butler J. J., Rodriguez V. Factors predicting for response and survival in adults with advanced non-Hodgkin's lymphoma. Arch Intern Med. 1978 Mar;138(3):413–418. [PubMed] [Google Scholar]
  8. Carbone P. P., Kaplan H. S., Musshoff K., Smithers D. W., Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971 Nov;31(11):1860–1861. [PubMed] [Google Scholar]
  9. Child J. A., Kushwaha M. R. Serum beta 2-microglobulin in lymphoproliferative and myeloproliferative diseases. Hematol Oncol. 1984 Oct-Dec;2(4):391–401. doi: 10.1002/hon.2900020409. [DOI] [PubMed] [Google Scholar]
  10. Child J. A., Spati B., Illingworth S., Barnard D., Corbett S., Simmons A. V., Stone J., Worthy T. S., Cooper E. H. Serum beta 2 microglobulin and C-reactive protein in the monitoring of lymphomas: findings in a multicenter study and experience in selected patients. Cancer. 1980 Jan 15;45(2):318–326. doi: 10.1002/1097-0142(19800115)45:2<318::aid-cncr2820450220>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  11. Costa A., Bonadonna G., Villa E., Valagussa P., Silvestrini R. Labeling index as a prognostic marker in non-Hodgkin's lymphomas. J Natl Cancer Inst. 1981 Jan;66(1):1–5. [PubMed] [Google Scholar]
  12. Crowther D., Lister T. A. The Cotswolds report on the investigation and staging of Hodgkin's disease. Br J Cancer. 1990 Oct;62(4):551–552. doi: 10.1038/bjc.1990.328. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Diamond L. W., Nathwani B. N., Rappaport H. Flow cytometry in the diagnosis and classification of malignant lymphoma and leukemia. Cancer. 1982 Sep 15;50(6):1122–1135. doi: 10.1002/1097-0142(19820915)50:6<1122::aid-cncr2820500616>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  14. Ferraris A. M., Giuntini P., Gaetani G. F. Serum lactic dehydrogenase as a prognostic tool for non-Hodgkin lymphomas. Blood. 1979 Oct;54(4):928–932. [PubMed] [Google Scholar]
  15. Fisher R. I., DeVita V. T., Jr, Johnson B. L., Simon R., Young R. C. Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy. Am J Med. 1977 Aug;63(2):177–182. doi: 10.1016/0002-9343(77)90230-3. [DOI] [PubMed] [Google Scholar]
  16. Gerdes J., Dallenbach F., Lennert K., Lemke H., Stein H. Growth fractions in malignant non-Hodgkin's lymphomas (NHL) as determined in situ with the monoclonal antibody Ki-67. Hematol Oncol. 1984 Oct-Dec;2(4):365–371. doi: 10.1002/hon.2900020406. [DOI] [PubMed] [Google Scholar]
  17. Griffin N. R., Howard M. R., Quirke P., O'Brien C. J., Child J. A., Bird C. C. Prognostic indicators in centroblastic-centrocytic lymphoma. J Clin Pathol. 1988 Aug;41(8):866–870. doi: 10.1136/jcp.41.8.866. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Hagberg H., Killander A., Simonsson B. Serum beta 2-microglobulin in malignant lymphoma. Cancer. 1983 Jun 15;51(12):2220–2225. doi: 10.1002/1097-0142(19830615)51:12<2220::aid-cncr2820511212>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  19. Jagannath S., Velasquez W. S., Tucker S. L., Fuller L. M., McLaughlin P. W., Manning J. T., North L. B., Cabanillas F. C. Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma. J Clin Oncol. 1986 Jun;4(6):859–865. doi: 10.1200/JCO.1986.4.6.859. [DOI] [PubMed] [Google Scholar]
  20. Jones R. A., Scott C. S., Norfolk D. R., Stark A. N., Child J. A. Cell surface expression of beta 2-microglobulin (beta 2m) correlates with stages of differentiation in B cell tumours. J Clin Pathol. 1987 May;40(5):486–489. doi: 10.1136/jcp.40.5.486. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Levine E. G., Arthur D. C., Frizzera G., Peterson B. A., Hurd D. D., Bloomfield C. D. There are differences in cytogenetic abnormalities among histologic subtypes of the non-Hodgkin's lymphomas. Blood. 1985 Dec;66(6):1414–1422. [PubMed] [Google Scholar]
  22. Levine E. G., Bloomfield C. D. Cytogenetics of non-Hodgkin's lymphoma. J Natl Cancer Inst Monogr. 1990;(10):7–12. [PubMed] [Google Scholar]
  23. Lister T. A., Crowther D., Sutcliffe S. B., Glatstein E., Canellos G. P., Young R. C., Rosenberg S. A., Coltman C. A., Tubiana M. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989 Nov;7(11):1630–1636. doi: 10.1200/JCO.1989.7.11.1630. [DOI] [PubMed] [Google Scholar]
  24. Morgan D. R., Williamson J. M., Quirke P., Clayden A. D., Smith M. E., O'Brien C. J., Allison D. L., Child J. A., Bird C. C. DNA content and prognosis of non-Hodgkin's lymphoma. Br J Cancer. 1986 Oct;54(4):643–649. doi: 10.1038/bjc.1986.221. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Pereira A., Cervantes F., Montserrat E., Llebaria C., Rozman C. Non-Hodgkin's lymphoma of unfavourable histology: a multivariate analysis of factors predicting the response to CHOP. Hematol Oncol. 1987 Jul-Sep;5(3):203–211. doi: 10.1002/hon.2900050307. [DOI] [PubMed] [Google Scholar]
  26. Roos G., Dige U., Lenner P., Lindh J., Johansson H. Prognostic significance of DNA-analysis by flow cytometry in non-Hodgkin's lymphoma. Hematol Oncol. 1985 Oct-Dec;3(4):233–242. doi: 10.1002/hon.2900030403. [DOI] [PubMed] [Google Scholar]
  27. Schneider R. J., Seibert K., Passe S., Little C., Gee T., Lee B. J., 3rd, Miké V., Young C. W. Prognostic significance of serum lactate dehydrogenase in malignant lymphoma. Cancer. 1980 Jul 1;46(1):139–143. doi: 10.1002/1097-0142(19800701)46:1<139::aid-cncr2820460122>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  28. Simonsson B., Nilsson K. 3H-thymidine uptake in chronic lymphocytic leukaemia cells. Scand J Haematol. 1980 Feb;24(2):169–173. doi: 10.1111/j.1600-0609.1980.tb02363.x. [DOI] [PubMed] [Google Scholar]
  29. Späti B., Child J. A., Kerruish S. M., Cooper E. H. Behaviour of serum beta 2-microglobulin and acute phase reactant proteins in chronic lymphocytic leukaemia. A multicentre study. Acta Haematol. 1980;64(2):79–86. doi: 10.1159/000207215. [DOI] [PubMed] [Google Scholar]
  30. Stetler-Stevenson M., Crush-Stanton S., Cossman J. Involvement of the bcl-2 gene in Hodgkin's disease. J Natl Cancer Inst. 1990 May 16;82(10):855–858. doi: 10.1093/jnci/82.10.855. [DOI] [PubMed] [Google Scholar]
  31. Swan F., Jr, Velasquez W. S., Tucker S., Redman J. R., Rodriguez M. A., McLaughlin P., Hagemeister F. B., Cabanillas F. A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels. J Clin Oncol. 1989 Oct;7(10):1518–1527. doi: 10.1200/JCO.1989.7.10.1518. [DOI] [PubMed] [Google Scholar]
  32. Tsujimoto Y., Cossman J., Jaffe E., Croce C. M. Involvement of the bcl-2 gene in human follicular lymphoma. Science. 1985 Jun 21;228(4706):1440–1443. doi: 10.1126/science.3874430. [DOI] [PubMed] [Google Scholar]
  33. Urba W. J., Duffey P. L., Longo D. L. Treatment of patients with aggressive lymphomas: an overview. J Natl Cancer Inst Monogr. 1990;(10):29–37. [PubMed] [Google Scholar]
  34. Vose J. M., Armitage J. O., Weisenburger D. D., Bierman P. J., Sorensen S., Hutchins M., Moravec D. F., Howe D., Dowling M. D., Mailliard J. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol. 1988 Dec;6(12):1838–1844. doi: 10.1200/JCO.1988.6.12.1838. [DOI] [PubMed] [Google Scholar]
  35. Weisenburger D. D., Linder J., Armitage J. O. Peripheral T-cell lymphoma: a clinicopathologic study of 42 cases. Hematol Oncol. 1987 Jul-Sep;5(3):175–187. doi: 10.1002/hon.2900050304. [DOI] [PubMed] [Google Scholar]
  36. Weiss L. M., Warnke R. A., Sklar J., Cleary M. L. Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N Engl J Med. 1987 Nov 5;317(19):1185–1189. doi: 10.1056/NEJM198711053171904. [DOI] [PubMed] [Google Scholar]
  37. Williamson J. M., Grigor I., Smith M. E., Holgate C. S., O'Brien C. J., Morgan D. R., Quirke P., Alison D. L., Child J. A., Bird C. C. Ploidy, proliferative activity, cluster differentiation antigen expression and clinical remission in high-grade non-Hodgkin's lymphoma. Histopathology. 1987 Oct;11(10):1043–1054. doi: 10.1111/j.1365-2559.1987.tb01844.x. [DOI] [PubMed] [Google Scholar]
  38. Yunis J. J., Mayer M. G., Arnesen M. A., Aeppli D. P., Oken M. M., Frizzera G. bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. N Engl J Med. 1989 Apr 20;320(16):1047–1054. doi: 10.1056/NEJM198904203201605. [DOI] [PubMed] [Google Scholar]
  39. van Krieken J. H., Raffeld M., Raghoebier S., Jaffe E. S., van Ommen G. J., Kluin P. M. Molecular genetics of gastrointestinal non-Hodgkin's lymphomas: unusual prevalence and pattern of c-myc rearrangements in aggressive lymphomas. Blood. 1990 Aug 15;76(4):797–800. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES